Source link : https://www.newshealth.biz/health-news/neoadjuvant-chemoradiation-plus-immunotherapy-boosts-responses-in-esophageal-cancer/
SAN FRANCISCO — Neoadjuvant chemoradiotherapy with or without the investigational PD-1 inhibitor sintilimab significantly increased pathological complete response (pCR) rates compared with neoadjuvant chemotherapy plus sintilimab in patients with locally advanced esophageal squamous cell carcinoma (ESCC), preliminary results from a randomized phase III trial in China showed. Among 146 patients, the pCR rate was 13% […]
Author : News Health
Publish date : 2025-01-24 21:13:43
Copyright for syndicated content belongs to the linked Source.